CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis & Neurotoxicity Research

Executive Summary: CA-074 is a nanomolar-potency, highly selective inhibitor of cathepsin B, a lysosomal cysteine protease crucial in cancer metastasis, neurotoxicity, and immune regulation. It demonstrates a Ki of 2–5 nM for cathepsin B, compared to 40–200 µM for cathepsins H and L, ensuring pathway specificity (APExBIO). CA-074’s efficacy in reducing breast cancer bone metastasis and suppressing Abeta42-induced neurotoxicity has been validated in vivo and in cell models (Liu et al. 2024). The compound is soluble in DMSO, ethanol, and water (with ultrasound), and shows negligible cytotoxicity at 10 mM in cell culture. Its application supports advanced mechanistic research on necroptosis, lysosomal membrane permeabilization, and immune modulation, as established by recent peer-reviewed studies.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in regulated cell death, tumor invasion, and immune signaling (Liu et al. 2024). During necroptosis, lysosomal membrane permeabilization (LMP) leads to the release of active cathepsins, including cathepsin B, which cleaves proteins critical for cell viability. Dysregulated cathepsin B activity contributes to cancer metastasis, bone resorption, and neuroinflammation. Targeting cathepsin B allows researchers to dissect proteolytic cascades underlying these pathologies (Related Article).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074, supplied by APExBIO, is a small-molecule inhibitor that forms a covalent adduct with the active-site cysteine of cathepsin B. Its chemical structure, (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid, provides high target affinity (Ki: 2–5 nM) and selectivity. CA-074 blocks proteolytic activity, preventing cleavage of substrates implicated in extracellular matrix remodeling, immune modulation, and neuronal cell death. In necroptosis models, CA-074 inhibits MLKL polymerization-induced lysosomal leakage, blunting cathepsin B-driven cell death (Liu et al. 2024). This distinguishes CA-074 from pan-cathepsin or non-cysteine protease inhibitors, supporting its use as a mechanistic probe in advanced cell death and metastasis studies (Contrast: Mechanistic Integration).

Evidence & Benchmarks

• CA-074 exhibits a cathepsin B inhibition constant (Ki) of 2–5 nM; Ki values for cathepsins H and L are 40–200 µM, confirming high selectivity (APExBIO).
• In a 4T1.2 breast cancer mouse model, intraperitoneal CA-074 at 50 mg/kg reduced bone metastasis without altering primary tumor size (Liu et al. 2024).
• CA-074 suppresses neurotoxicity in microglial cell cultures exposed to Abeta42 peptides, a model of Alzheimer’s disease (APExBIO).
• Inhibition of cathepsin B with CA-074 protects cells from necroptosis by blocking MLKL-induced lysosomal membrane permeabilization (Liu et al. 2024).
• In vitro, CA-074 demonstrates negligible cytotoxicity at concentrations up to 10 mM in standard cell lines (APExBIO).
• CA-074 modulates immune responses by shifting helper T cell activity from Th-2 to Th-1, reducing IgE and IgG1 levels (Updated Immune Modulation).

Applications, Limits & Misconceptions

CA-074 is validated for:

• Dissecting cathepsin B contribution to cancer metastasis and bone invasion.
• Studying regulated cell death (necroptosis), including MLKL and lysosomal pathways.
• Probing neurotoxicity mechanisms in microglial and neuronal systems.
• Immune response modulation, especially Th-2 to Th-1 helper T cell switching.

Compared to comprehensive roadmaps, this article focuses on recent necroptosis insights and CA-074’s selectivity for translational workflows.

Common Pitfalls or Misconceptions

• CA-074 is not effective against non-cysteine proteases or pan-cathepsin targets—its selectivity is limited to cathepsin B.
• In vivo efficacy depends on delivery route; oral administration has not been validated for metastasis models.
• Solubility in water requires ultrasonic assistance; improper preparation can limit bioavailability.
• Long-term storage (>1 month) of working solutions is discouraged; chemical stability is optimal at -20°C for solids.
• CA-074 does not reverse established metastatic lesions but suppresses further dissemination (Contrast: Workflow Guidance).

Workflow Integration & Parameters

CA-074 is provided as a powder for reconstitution. For in vitro assays, dissolve in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water with sonication (>5.91 mg/mL). For in vivo mouse studies, intraperitoneal injection of 50 mg/kg is standard. Solutions should be used immediately or stored short-term at -20°C. CA-074 is compatible with cell viability, necroptosis, migration, and immune modulation assays. At 10 mM, CA-074 exhibits negligible cytotoxicity in standard culture conditions. For details, see the CA-074, Cathepsin B inhibitor product page (SKU: A1926).

Conclusion & Outlook

CA-074 represents a benchmark tool for selective cathepsin B inhibition in cancer metastasis, regulated cell death, and neurotoxicity research. Its high selectivity and well-validated in vivo efficacy enable precise mechanistic dissection and translational innovation. Ongoing studies continue to expand its role in immune modulation and advanced disease modeling. For further mechanistic and application guidance, see related articles on nanomolar-potency inhibition and translational strategy.